ReviewCurrent rheumatology reports2020
Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future.
Review in Current rheumatology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 44 citations in OpenAlex.
- Childhood-Onset Takayasu Arteritis With Extensive Vascular Involvement: A Four-Decade Follow-Up Case Report.Case reports in rheumatology · 2026Article
- Article
- Takayasu arteritis presenting with severe biventricular dysfunction and renal artery stenosis in a pediatric patient: a case report.Annals of medicine and surgery (2012) · 2025Article
- The Glucocorticoid Receptor: Isoforms, Functions, and Contribution to Glucocorticoid Sensitivity.Endocrine reviews · 2024Review
- Article
- Thrombosis in vasculitis: An updated review of etiology, pathophysiology, and treatment.Heliyon · 2024Review
- Temporal artery biopsy in giant cell arteritis: clinical perspectives and histological patterns.Frontiers in medicine · 2024Review
- Ischemic stroke as the first clinical manifestation of an initially undiagnosed case of Takayasu arteritis in a young woman from Ethiopia: A case report.SAGE open medical case reports · 2024Article
- Secondary Amyloidosis Treated with Tocilizumab as a Complication of Temporal Arteritis.European journal of case reports in internal medicine · 2024Article
- Oxidative Stress: A Suitable Therapeutic Target for Optic Nerve Diseases?Antioxidants (Basel, Switzerland) · 2023Review
- Takayasu Arteritis: A Difficult Diagnosis in a Patient With an Extensive Cardiovascular History.Cureus · 2023Article
- Longitudinal Characterization of Vascular Inflammation and Disease Activity in Takayasu Arteritis and Giant Cell Arteritis: A Single-Center Prospective Study.Arthritis care & research · 2023Observational
- Article
- [Biologics for connective tissue diseases and vasculitides].Der Internist · 2022Review
- Performance of leflunomide as a steroid-sparing agent in giant cell arteritis: A single-center, open-label study.Frontiers in medicine · 2022Article
- Cardiovascular Risk in Patients With Takayasu Arteritis Directly Correlates With Diastolic Dysfunction and Inflammatory Cell Infiltration in the Vessel Wall: A Clinical,Frontiers in medicine · 2022Article
- [Glucocorticoids in the treatment of giant cell arteritis : How much, how long and how to spare?]Zeitschrift fur Rheumatologie · 2021Review
- Multisystemic Sarcoidosis Presenting With Leg Ulcers, Pancytopenia, and Polyserositis Was Successfully Treated With Glucocorticoids: A Case Report and Literature Review.Frontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
purpose of reviewGuidelines for the management of large vessel vasculitides have been recently updated by several scientific societies. We have evaluated the current recommendations for treatment of giant cell arteritis (GCA) and Takayasu arteritis (TA) and addressed potential future therapeutic strategies. RECENT
findingsWhile glucocorticoids (GCs) remain the gold standard for induction of remission, many patients relapse and acquire high cumulative GC exposure. Thus, GC-sparing therapies such as methotrexate are recommended for selected patients with GCA and all patients with TA. Recent high-quality evidence shows that tocilizumab is an effective GC-sparing agent in GCA. Non-biologic and biologic immunomodulators also appear to have GC-sparing properties in TA. Tocilizumab is now considered to be part of the standard treatment for GCA, particularly with relapsing disease, but questions on its use such as length of treatment and monitoring of disease activity remain open. High-quality evidence to guide treatment of TA is still lacking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.